Biomira

Biomira Inc. (TSE: BRA; Nasdaq: BIOM) is a product focused biotechnology company applying its proprietary immunotherapy and organic chemistry technologies for the development of cancer therapeutics. The Company's lead product, THERATOPE® vaccine, is currently being tested in a Phase III clinical trial for metastatic breast cancer. The Company's commitment to the development of products for the treatment of cancer is focused on synthetic therapeutic vaccines and innovative strategies for immunotherapeutic treatment of cancer. The vision at Biomira is clear and simple-we intend to build a profitable company based on the discovery and development of vaccines and related immunotherapeutic products for the treatment of cancer. We are The Cancer Vaccine PeopleTM.

Contact Details: 2011-94 Street Edmonton T6N 1H1 Canada Tel: (780) 450-3761 Fax: (780) 463-0871 Email: dbrunner@biomira.com WWW: www.biomira.com/

Loading...

Recent Publications by Biomira:
Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity. Structurally defined immunostimulatory adjuvants play important roles in...	27th June, 2007	Biomira Inc., 2011-94 Street, Edmonton, Alberta, Canada T6N 1H1.	Carbohydr Res. 2007 May 7;342(6):784-96. Epub 2007 Jan 26. DOI Direct Link
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. PURPOSE: Men with biochemical failure after radical prostatectomy have few...	28th July, 2006	Cross Cancer Institute and Biomira, Inc., 11560 University Avenue,	J Urol. 2006 Jul;176(1):91-5. DOI Direct Link
Synthetic vaccines: the role of adjuvants in immune targeting. A clear understanding of the mechanism of function of immune stimulatory...	26th March, 2004	Biomira Inc., 2011 94 Street, Edmonton, Alberta, T6N 1H1, Canada.	Curr Med Chem. 2003 Aug;10(15):1423-39.
Lipid A structures containing novel lipid moieties: synthesis and adjuvant properties. Structurally well-defined immune stimulatory molecules are important...	17th May, 2003	Biomira Inc., 2011-94 Street, Edmonton, T6N 1H1, Alberta, Canada.	Bioorg Med Chem Lett. 2002 Aug 19;12(16):2193-6.

Biomira Patents:
US Patent No.	Title
6600012	Lipid-modified muc-1 derivatives
4971795	Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
5055562	Fluorocarbon chain-containing antigenic conjugates
5075218	Screening for antibodies which bind carbohydrate epitopes of tumor-associated antigens, and uses thereof
5110911	Human tumor-associated Thomsen-Friedenreich antigen
→View more Biomira patents.

Biomira (BIOM) Financial information Links from Barchart
BIOM Quote from from Barchart.com
BIOM Chart from from Barchart.com
BIOM Profile from from Barchart.com
BIOM Opinion from from Barchart.com
→View more Biomira finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 574 times since April 2007, the link to the organisation's website has been followed 108 times

Recent Search Terms used to find this page: biomira | biomira | biomira | biomira canada | biomira edmonton | Biomira | biomira canada homepage | biomira canada homepage | biomira canada homepage | biomira building edmonton alberta | .

Search for more companies in Edmonton

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Biomira